WHO Expert Committee on Selection and Use of Essential Medicines - WHO Technical Report Series, No. 850, Annex 3 (Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Products) - Sixth Report
(1995; 36 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoINTRODUCTION
Ver el documentoGLOSSARY
Abrir esta carpeta y ver su contenido1. PROVISIONS AND PREREQUISITES FOR A CLINICAL TRIAL
Ver el documento2. THE PROTOCOL
Abrir esta carpeta y ver su contenido3. PROTECTION OF TRIAL SUBJECTS
Abrir esta carpeta y ver su contenido4. RESPONSIBILITIES OF THE INVESTIGATOR
Abrir esta carpeta y ver su contenido5. RESPONSIBILITIES OF THE SPONSOR
Abrir esta carpeta y ver su contenido6. RESPONSIBILITIES OF THE MONITOR
Abrir esta carpeta y ver su contenido7. MONITORING OF SAFETY
Abrir esta carpeta y ver su contenido8. RECORD KEEPING AND HANDLING OF DATA
Abrir esta carpeta y ver su contenido9. STATISTICS AND CALCULATIONS
Cerrar esta carpeta10. HANDLING OF AND ACCOUNTABILITY FOR PHARMACEUTICAL PRODUCTS
Ver el documento10.1 Supply and storage
Ver el documento10.2 Investigational labelling and packaging
Ver el documento10.3 Responsibilities of the investigator
Ver el documento10.4 Responsibilities of the sponsor and monitor1
Abrir esta carpeta y ver su contenido11. ROLE OF THE DRUG REGULATORY AUTHORITY
Ver el documento12. QUALITY ASSURANCE FOR THE CONDUCT OF A CLINICAL TRIAL
Ver el documento13. CONSIDERATIONS FOR MULTICENTRE TRIALS
Ver el documentoREFERENCES
Ver el documentoAPPENDIX 1: World Medical Association’s Declaration of Helsinki1
Ver el documentoAPPENDIX 2: Model list of items to be contained in a clinical trial protocol
 

10.4 Responsibilities of the sponsor and monitor1

1 See also sections 5 and 6.

The sponsor is responsible for:

• Supplying the investigational and, when appropriate, comparator product(s), prepared in accordance with principles of Good Manufacturing Practice. The products should be fully characterized, properly coded, and suitably packaged in such a way as to provide protection against deterioration during transport and storage at intermediate destinations; appropriate investigational labelling should be affixed (see Section 10.2).

• Ensuring that the package of investigational product(s) is of a size suitable for the trial and adequate for the trial subjects.

• Keeping sufficient samples from each batch used in the trial as a reference for control tests and validation of data, as required in national regulations.

• Providing information about the expiry date (month/year) or retest date information in a manner understandable to all staff involved in the trial.

During the visits to the clinical trial site, the monitor should check:

• That all study products for the trial are used exclusively within the limits defined by the protocol.

• That inventory records of study products are in order and that there are sufficient supplies.

• That the expiry dates are not likely to be, or have not been, exceeded.

• That the storage conditions for study products are adequate.

• Procedures for and records of returned and/or unused study products.

 

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013